Journey was Fortress Biotech’s largest segment in fiscal 2025, bringing in $61.86M of $63.26M (98%).
| Segment | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Journey | — | $79.18M | $56.13M | $61.86M | |||||||
| Dermatology Products Sales | $73.67M | — | — | — | |||||||
| Financial Service Activities | — | — | — | — | |||||||
| Fortress | — | $5.23M | $1.50M | — | |||||||
| Pharmaceutical & Biotechnology Product Development | $2.07M | — | — | — | |||||||
| Avenue | — | — | — | $1.40M | |||||||
| Checkpoint Merger | — | — | $41.00K | — | |||||||
| Checkpoint Common Stock Warrants | — | $103.00K | — | — | |||||||
| Total | $75.74M | $84.51M | $57.68M | $63.26M |
Fortress Biotech brought in $63.26M from its two segments in fiscal 2025, the year ended December 31, 2025. Fortress Biotech regrouped these segments after fiscal 2024, so the total does not compare directly with that year's $57.68M. Journey was the largest at $61.86M (97.8%), ahead of Avenue at $1.40M (2.2%).
Fortress Biotech began breaking out Journey in fiscal 2023 and Avenue in fiscal 2025. Fortress Biotech stopped reporting Dermatology Products Sales ($73.67M in fiscal 2022), Pharmaceutical & Biotechnology Product Development ($2.07M in fiscal 2022), Fortress ($1.50M in fiscal 2024) and two others as separate segments.
Qbrexza was Fortress Biotech’s largest product and service line in fiscal 2024, bringing in $25.11M of $56.63M (44%).
| Product and Service | FY 2024 |
|---|---|
| Qbrexza | $25.11M |
| Accutane | $19.41M |
| Foam Franchise Products (Amzeeq & Zilxi) | $6.65M |
| Other / Legacy Product Revenue | $3.96M |
| Collaboration Revenue | $1.50M |
| Total | $56.63M |
Fortress Biotech brought in $56.63M from its five product and service lines in fiscal 2024, the year ended December 31, 2024. Qbrexza was the largest at $25.11M (44.3%), ahead of Accutane at $19.41M (34.3%) and Foam Franchise Products (Amzeeq & Zilxi) at $6.65M (11.7%). The other two lines brought in $5.46M combined.
National Holdings Corporation was Fortress Biotech’s largest revenue line in fiscal 2016, bringing in $10.32M of $16.48M (63%).
| Consolidated Entities | FY 2015 | FY 2016 |
|---|---|---|
| National Holdings Corporation | — | $10.32M |
| Parent Company | $863.00K | $6.16M |
| Total | $863.00K | $16.48M |
Fortress Biotech brought in $16.48M from its two revenue lines in fiscal 2016, the year ended December 31, 2016. Fortress Biotech regrouped these revenue lines after fiscal 2015, so the total does not compare directly with that year's $863.00K. National Holdings Corporation was the largest at $10.32M (62.6%), ahead of Parent Company at $6.16M (37.4%).
Fortress Biotech began breaking out National Holdings Corporation in fiscal 2016, when it brought in $10.32M.
Fortress Biotech (FBIO) reports its revenue by segment, by product and service and by consolidated entities. In fiscal 2025, Journey was its largest segment, bringing in $61.86M (97.8% of the total), followed by Avenue at $1.40M (2.2%).
Journey was Fortress Biotech's largest segment in fiscal 2025, bringing in $61.86M, or 97.8% of the $63.26M total across its two segments.
Qbrexza was Fortress Biotech's largest product and service line in fiscal 2024, bringing in $25.11M, or 44.3% of the $56.63M total across its five product and service lines.
National Holdings Corporation was Fortress Biotech's largest revenue line in fiscal 2016, bringing in $10.32M, or 62.6% of the $16.48M total across its two revenue lines.
Every figure comes from Fortress Biotech's annual financial filings, as reported. Each line keeps the name Fortress Biotech gives it, and years follow its fiscal calendar.
Fortress Biotech's revenue by segment goes back to fiscal 2015, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.